Overview
Announcements

Methodology Change | Solactive Pharma Breakthrough Value Index | Effective Date 13/02/2023

Today, on the 31/01/2023, Solactive announces the following changes to the methodology of the following index (the ‘Affected Index’):

NAME

RIC

ISIN

Solactive Pharma Breakthrough Value Index

.SOLBIOT

DE000SLA30N4

 

Rationale for Methodology Change

The Index aims to track the performance of a basket of stocks of companies that are actively engaged in the research, development and/or manufacturing of orphan drugs.

As per the current selection process of the Index, there is no exclusion criteria for filtering out ESG non-compliant companies. There is however an ever more increasing demand for ESG compliant investments in the market in general which is among others driven by regulatory requirements.

Solactive has determined that the methodology of the Index shall be amended to include the ESG activity screens from a restrictive exclusion list. The suggested enhanced list will screen the companies on various criteria related to ESG. A more detailed overview of the considered activities can be found below in section “Proposed Changes to the Index Guideline”.

Additionally, to ensure investability of the Index as well as reflect the actual liquidity available in the market, the weighting concept is proposed to be amended.

Changes to the Index Guideline

The following Methodology changes will be implemented in the following points of the Index Guideline (ordered in accordance with the numbering of the affected sections):

Section 1.10 Index Universe

Old text:

On each Selection Day that occurs in the month of March, the Index Universe shall be determined based on orphan drug related company data provided by EvaluatePharma as described below. On each Selection Day that occurs in the month of September, the Index Universe shall remain unchanged from the Index Universe determined on the immediately preceding Selection Day.

[…]

New text:

On each Selection Day that occurs in the month of March, the Index Universe shall be determined based on orphan drug related company data provided by EvaluatePharma as described below. On each Selection Day that occurs in the month of September, the Index Universe shall remain unchanged from the Index Universe determined on the immediately preceding Selection Day.

[…]

On each Selection Day, any company included in the ESG Exclusions Enhanced Index as determined by Solactive is then excluded from the Index Universe. Further, any company that is not a part of the Index Universe of the ESG Exclusions Enhanced Index as of the immediately preceding Selection Day of the ESG Exclusions Enhanced Index, shall be excluded from the Index Universe.

The ESG Exclusions Enhanced Index is reconstituted by Solactive on a semi-annual basis and the methodology by reference to which the ESG Exclusions Enhanced Index is constructed, together with the most recent applicable categories and inclusion criteria, is available on the Solactive website.

The applicable categories and inclusion criteria of the ESG Exclusions Enhanced Index as of 28th of February 2022 are set out in Annex C of this document.

 

Section 2.2 Ordinary Adjustment

Old text:

[…]

In respect of each Selection Day immediately preceding such Adjustment Day that is a Rebalancing Day, each Index Component is weighted equally such that the total Index Component Weight of all Index Components is equal to 100%, subject to the following constraints:

  1. if the 3m Average Daily Value Traded is less than USD 2,000,000, then the Index Component Weight of such Index Component shall be capped at 1% provided the initial weight is greater than 1%;
  2. if the 3m Average Daily Value Traded is less than USD 3,000,000 but greater than or equal to USD 2,000,000, then the Index Component Weight of such Index Component shall be capped at 2% provided the initial weight is greater than 2%; and

iii.    if the 3m Average Daily Value Traded is less than USD 4,000,000 but greater than or equal to USD 3,000,000, then the Index Component Weight of such Index Component shall be capped at 3% provided the initial weight is greater than 3%.

Any residual weight that arises from capping the Index Component Weights shall be distributed equally to the remaining Index Components, subject to the constraints i-iii above. For the avoidance of doubt, Index Components affected from the aforementioned constraints will be excluded from the weight redistribution if this process increases their weight above the defined weight caps.

[…]

New text:

[…]

On each Selection Day each Index Component is weighted in accordance with the following steps

  1. Each Index Component is initially weighted equally ;
  2. Then, for each Index Component the maximum weight is calculated as:

where,

and,

AuM refers to the maximum of total assets under management in US Dollars of ETFs tracking the index as listed in Annex D and US Dollars 50 million;

Haircut assumed to be 10%;

Liquidity Measure refers to the 3-month Average Daily Value Traded in US Dollars;

Market Cap refers to the Free Float Market Capitalization of a company in US Dollars;

Max Ownership assumed to be 7.5%;

Participation (%) assumed to be 100%;

Turnover refers to the hypothetical fund turnover in respect of each rebalancing date and is assumed to be 40%.

  • In respect of Index Components whose initial weight is  greater than , the Target Index Weight  shall be set to be equal to , and the excess weight is then calculated as follows:

The cumulative excess weight is calculated as the sum of  in respect of all Index Components whose initial weight  is  greater than .

The cumulative excess weight is then proportionally distributed across all Index Components whose initial weight   is less than  such that the above maximum weight cap condition is fulfilled. This can be an iterative process until 100% weight is fully allocated and all conditions above are fulfilled.

[…]

The Annex C and Annex D is proposed to be be included.

Annex C

As of February 2022, the following inclusion criteria for the categories below were applicable.

Please refer to the most recent document available under the URL as specified in section ‘2.1. Index Universe Requirements’ above for the most recent applicable categories and inclusion criteria.

Categories

Inclusion criterion

Established norms around Environment, Human Rights, Corruption and Labour Rights

Non-Compliance with the UNGC

Controversy

Controversies with the Level 5

Tobacco

(5% Production <OR> 5% Retail <OR> 5% Related Products/Services)*

Defense – Weapons

(5% Military Contracting Weapons <OR> 5% Military Contracting Weapons – Related Products/Services)*

Defense – Controversial Weapons

Any direct Involvement or any indirect Involvement through corporate ownership

Small Arms

(5% Civilian customers (Assault and non-assault weapons) <OR> 5% Key Components <OR>  5% Military/law enforcement customers <OR>  5% Retail/Distribution)*

Coal

(5% Thermal Coal Extraction <OR> 5% Power Generation <OR> 5% Supporting Products/Services <OR> Power Generation Capacity Increase)*

Conventional Oil & Gas

(5% Generation <OR> 5% Production <OR> 5% Supporting Products/Services <OR> Capacity Increase) *

Unconventional Oil & Gas

(5% Oil Sands Extraction <OR> 5% Artic Oil & Gas Exploration/Extraction <OR> 5% Shale Energy Extraction <OR> Capacity Increase)*

Nuclear Power

(5% Production <OR> 5% Distribution <OR> 5% Supporting Products <OR> Capacity Increase)*

Alcohol

(5% Production <OR> 5% Retail <OR> 5% Related Products/Services)*

Gambling

(5% Operations <OR> 5% Specialized Equipment <OR> 5% Supporting Products/Services)*

Adult Entertainment

(5% Production <OR> 5% Distribution)*

Note:

·        % figures refer to revenue threshold (for degree of involvement). The criterion is fulfilled if involvement is equal to or above such threshold.

·        Capacity increase refers to any increase in capacity from the immediately preceding Selection Day of the ESG Exclusions Enhanced Index

·        The terminology used in the table above is specific to the Data Provider II and may change from time to time.

 

*This includes significant corporate ownership (were a company holds a stake greater than 50% in an involved company, the revenues of the involved company are attributed to the company).

 

Any company which fulfills any of the criteria set out above shall be a component of the ESG Exclusions Enhanced Index. The primary listing for each company is selected as Index Component of the ESG Exclusions Enhanced Index. For the avoidance of doubt, any company for which an evaluation of the criteria is not possible due to the non-availability of relevant data from the Data Provider II, shall be a component of the ESG Exclusions Enhanced Index.

 

Annex D

Name of the ETF used to determine the AuM: L&G Pharma Breakthrough UCITS ETF, ISIN: IE00BF0H7608

 

 

Defined terms used in this announcement, but not defined herein, have the meaning assigned to them in the respective index guideline of the Affected Indices. The amended version of the index guideline will be available on the effective date.